Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Supernus Pharmaceuticals Inc    SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
46.9(c) 47.9(c) 49.9(c) 48.9(c) 49 Last
648 175 589 982 793 218 1 025 701 111 104 Volume
+1.96% +2.13% +4.18% -2.00% +0.20% Change
More quotes
Financials (USD)
Sales 2018 400 M
EBIT 2018 132 M
Net income 2018 103 M
Finance 2018 202 M
Yield 2018 -
Sales 2019 478 M
EBIT 2019 187 M
Net income 2019 136 M
Finance 2019 303 M
Yield 2019 -
P/E ratio 2018 25,78
P/E ratio 2019 19,82
EV / Sales2018 5,88x
EV / Sales2019 4,70x
Capitalization 2 553 M
More Financials
Company
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.The firm also develops product candidates for the... 
Sector
Pharmaceuticals
Calendar
10/03 | 02:35pmPresentation
More about the company
Surperformance© ratings of Supernus Pharmaceuticals I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUPERNUS PHARMACEUTICALS I
09/21SUPERNUS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
AQ
09/20Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conferenc..
GL
09/18SUPERNUS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other..
AQ
09/18SUPERNUS PHARMACEUTICALS : to Acquire Biscayne Neurotherapeutics
AQ
09/13Supernus to Acquire Biscayne Neurotherapeutics
GL
09/11SUPERNUS PHARMACEUTICALS : Wins Appeal on Oxtellar XR against TWi
AQ
09/07SUPERNUS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
AQ
09/06Supernus Wins Appeal on Oxtellar XR® against TWi
GL
09/06TODAY'S RESEARCH REPORTS ON TRENDING : Momenta Pharmaceuticals and Supernus Phar..
AC
09/04SUPERNUS PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events, Financial..
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
08:30aASTRAZENECA : Mixed Results from Farxiga Trial
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
03:05aAs China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
09/23Supernus Pharmaceuticals $SUPN Rating Increased to Buy at ValuEngine  
09/22Supernus Pharmaceuticals $SUPN Downgraded by BidaskClub to “Hold”
1
09/21Co’s that have issued in the last 30 days $MU $PIR $SCS $UNFI $DRI $RHT $ML..
2
09/20Co’s that have issued in the last 30 days $DRI $RHT $MLHR $CBRL $GIS $BWA $.. 
09/20Supernus Pharmaceuticals $SUPN Downgraded by BidaskClub to Hold  
More tweets
Qtime:65
News from SeekingAlpha
09/13Supernus Pharma to acquire Biscayne Neurotherapeutics for up to $185M 
09/06Supernus prevails on appeal of Oxtellar XR patents by TWi Pharma 
08/08Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q2 2018 Results - Earnin.. 
08/07Supernus Pharmaceuticals beats by $0.14, misses on revenue 
08/06Notable earnings after Tuesday?s close 
Chart SUPERNUS PHARMACEUTICALS INC
Duration : Period :
Supernus Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUPERNUS PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 60,3 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Jack A. Khattar President, CEO, Secretary & Director
Charles W. Newhall Chairman
Gregory S. Patrick Chief Financial Officer & Vice President
Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President
Stefan K. F. Schwabe Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SUPERNUS PHARMACEUTICALS INC22.71%2 605
ABBVIE-4.60%140 343
MERCK KGAA-2.89%13 233
KYOWA HAKKO KIRIN CO LTD-6.21%10 668
JAZZ PHARMACEUTICALS PLC21.63%9 929
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD53.61%8 308